Company intelligence / Profile preview

Herantis Pharma

Helsinki, Finlandherantis.com ↗
Ownership
Public · HRTIS
Employees
~10
Development stage
Other
01

Overview

Herantis’ lead product, HER‑096, has completed Phase 1a with positive safety and tolerability results in healthy volunteers. The ongoing Phase 1b trial in Parkinson’s patients aims to demonstrate safety and tolerability of repeated subcutaneous doses. Pharmacokinetic data show efficient blood-brain barrier penetration and CSF concentrations within the predicted active range. Topline data from the patient cohort are expected Q3 2025[6][9][10].

Therapeutic areas
Neurology
Modalities
small synthetic peptides/peptidomimetics
Industry
Biotech
02

Drug pipeline

6 assets

cis-Urocanic acid

2

5 more assets in the full pipeline.

03

Partnerships

Long-term collaboration with Medfiles for clinical trial operations since 2009[3].Contract Research Services Turku – CRST Oy runs current clinical trials[9].No major pharma partnerships disclosed.
04

Financials

Market cap
$32.8M
Total revenue
$0
Enterprise value
$32.7M

Beyond the preview

Go deeper on Herantis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herantis Pharma.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call